Dear Members of the Committee on Health Coverage, Insurance and Financial Services: As state and national organizations representing a wide range of U.S. taxpayers and consumers, we write today in opposition to LD 1117, Maine’s Act To Prevent Excessive Prices for Prescription Drugs, which seeks to impose pricing constraints on generic drug manufacturers. While working […]
Soaring prescription drug prices are putting financial pressure on families across the country. In response, state legislators are increasingly considering limits on the annual price increase of prescription drugs. But rather than making drugs more affordable, these policies risk reducing consumer access to cheaper, generic alternatives. Read this op-ed in The Hill […]
Today, ACI joined twenty-two other nonprofits in support of legislation that would reduce the cost of medications by providing Medicare patients access to lower-cost generic drugs and biosimilars. The letter is available online.
While the Lower Health Care Costs Act is intended to increase competition and patient access to lower cost medicines, section 205 of the bill needs to address FDA concerns about the “parking” of generic applications. We believe generic manufacturers need to launch new medications into the market as soon as possible after approval. However, as […]
A coalition of nonprofit think tanks sent a letter to FDA Commissioner Sharpless urging reforms to current regulatory regulations that are impeding market competition between drug makers. The letter states that increasing market competition is the best means for price reductions, which will lower medical program costs, taxpayer burdens, and out-of-pocket expenses for consumers, as […]